Scott Wasserman, Amgen's head of cardiovascular and metabolic therapies, told Reuters that the company does not believe there is a safety issue.
Neurocognitive side effects were also more common in the treatment arm of an 18-month, 2,300-patient trial of a rival PCSK9 drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc.
The drug, Praluent, was shown to reduce the risk of cardiovascular problems from 3.3 percent for placebo patients to 1.7 percent for the treatment group. "Events" in this trial were defined only as death, heart attack, stroke and chest pain requiring hospitalization.
Scott Wasserman, Amgen's head of cardiovascular and metabolic therapies, told Reuters that the company does not believe there is a safety issue.Neurocognitive side effects were also more common in the treatment arm of an 18-month, 2,300-patient trial of a rival PCSK9 drug being developed by Sanofi SA and Regeneron Pharmaceuticals Inc.The drug, Praluent, was shown to reduce the risk of cardiovascular problems from 3.3 percent for placebo patients to 1.7 percent for the treatment group. "Events" in this trial were defined only as death, heart attack, stroke and chest pain requiring hospitalization.
การแปล กรุณารอสักครู่..